|
Gene: SPATA2L |
Gene summary for SPATA2L |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPATA2L | Gene ID | 124044 |
Gene name | spermatogenesis associated 2 like | |
Gene Alias | C16orf76 | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IUW3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
124044 | SPATA2L | LZE24T | Human | Esophagus | ESCC | 1.72e-14 | 3.40e-01 | 0.0596 |
124044 | SPATA2L | P1T-E | Human | Esophagus | ESCC | 6.99e-04 | 2.20e-01 | 0.0875 |
124044 | SPATA2L | P2T-E | Human | Esophagus | ESCC | 1.96e-10 | 1.34e-01 | 0.1177 |
124044 | SPATA2L | P4T-E | Human | Esophagus | ESCC | 1.45e-04 | 1.26e-01 | 0.1323 |
124044 | SPATA2L | P5T-E | Human | Esophagus | ESCC | 6.56e-07 | 1.33e-01 | 0.1327 |
124044 | SPATA2L | P8T-E | Human | Esophagus | ESCC | 2.20e-13 | 1.54e-01 | 0.0889 |
124044 | SPATA2L | P9T-E | Human | Esophagus | ESCC | 4.85e-04 | 1.18e-01 | 0.1131 |
124044 | SPATA2L | P10T-E | Human | Esophagus | ESCC | 5.84e-03 | 1.53e-02 | 0.116 |
124044 | SPATA2L | P11T-E | Human | Esophagus | ESCC | 9.71e-04 | 2.23e-01 | 0.1426 |
124044 | SPATA2L | P12T-E | Human | Esophagus | ESCC | 2.02e-07 | 2.26e-01 | 0.1122 |
124044 | SPATA2L | P15T-E | Human | Esophagus | ESCC | 4.66e-03 | 8.88e-02 | 0.1149 |
124044 | SPATA2L | P16T-E | Human | Esophagus | ESCC | 1.77e-03 | 8.90e-02 | 0.1153 |
124044 | SPATA2L | P20T-E | Human | Esophagus | ESCC | 5.06e-06 | 1.51e-01 | 0.1124 |
124044 | SPATA2L | P21T-E | Human | Esophagus | ESCC | 1.33e-10 | 1.61e-01 | 0.1617 |
124044 | SPATA2L | P22T-E | Human | Esophagus | ESCC | 3.60e-10 | 1.36e-01 | 0.1236 |
124044 | SPATA2L | P23T-E | Human | Esophagus | ESCC | 5.00e-16 | 4.16e-01 | 0.108 |
124044 | SPATA2L | P24T-E | Human | Esophagus | ESCC | 1.60e-08 | 1.25e-01 | 0.1287 |
124044 | SPATA2L | P26T-E | Human | Esophagus | ESCC | 3.64e-12 | 1.97e-01 | 0.1276 |
124044 | SPATA2L | P27T-E | Human | Esophagus | ESCC | 2.82e-10 | 1.67e-01 | 0.1055 |
124044 | SPATA2L | P28T-E | Human | Esophagus | ESCC | 2.78e-16 | 2.52e-01 | 0.1149 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | |
Breast | IDC | |
Breast | DCIS | |
Cervix | CC | |
Cervix | HSIL_HPV |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPATA2L | SNV | Missense_Mutation | rs141882327 | c.703G>A | p.Glu235Lys | p.E235K | Q8IUW3 | protein_coding | tolerated(0.56) | possibly_damaging(0.496) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
SPATA2L | SNV | Missense_Mutation | c.397G>C | p.Asp133His | p.D133H | Q8IUW3 | protein_coding | deleterious(0) | possibly_damaging(0.82) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
SPATA2L | SNV | Missense_Mutation | rs201257207 | c.941G>A | p.Arg314His | p.R314H | Q8IUW3 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SPATA2L | insertion | In_Frame_Ins | novel | c.592_593insTTGAGCATTTGAATCACA | p.Trp198delinsPheGluHisLeuAsnHisArg | p.W198delinsFEHLNHR | Q8IUW3 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
SPATA2L | SNV | Missense_Mutation | rs778998399 | c.1208N>A | p.Arg403Gln | p.R403Q | Q8IUW3 | protein_coding | tolerated(1) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPATA2L | SNV | Missense_Mutation | rs771688020 | c.1093N>A | p.Ala365Thr | p.A365T | Q8IUW3 | protein_coding | tolerated(0.77) | benign(0) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
SPATA2L | SNV | Missense_Mutation | c.1030T>C | p.Ser344Pro | p.S344P | Q8IUW3 | protein_coding | tolerated(0.31) | benign(0.017) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPATA2L | SNV | Missense_Mutation | rs759117848 | c.1229C>T | p.Ala410Val | p.A410V | Q8IUW3 | protein_coding | deleterious(0.01) | benign(0.165) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SPATA2L | SNV | Missense_Mutation | c.1135N>A | p.Ala379Thr | p.A379T | Q8IUW3 | protein_coding | tolerated(0.14) | benign(0.013) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SPATA2L | SNV | Missense_Mutation | rs760286527 | c.857N>T | p.Pro286Leu | p.P286L | Q8IUW3 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-DM-A28K-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |